Analyst firms · Robert W. Baird · FTRE
Robert W. Baird FTRE price target and rating history
Fortrea Holdings Inc. (FTRE) · Health Care
Robert W. Baird rates Fortrea Holdings Inc. (FTRE) Outperform with a $9 price target, as of its latest action on Aug 4, 2025. It has published 3 rating actions on FTRE since March 2024, including 1 upgrade and 1 downgrade. Across 8 firms with a FTRE price target in the last 12 months, the median target is $22.
- Current rating
- Outperform
- Price target
- $9
- Median target, all firms
- $22
- Actions on FTRE
- 3
Robert W. Baird price target on FTRE
Every Robert W. Baird rating on FTRE
- Aug 4, 2025
- Dec 6, 2024
- Mar 22, 2024
How other firms rate FTRE
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Mizuho | Underperform | $19 | Nov 11, 2026 |
| Deutsche Bank | Buy | $25 | Oct 15, 2026 |
| Barclays | Overweight | $23 | Oct 6, 2026 |
| UBS | Neutral | $22 | Sep 30, 2026 |
| TD Cowen | Buy | $15 | Mar 9, 2026 |
| Truist Securities | Buy | $22 | Jan 8, 2026 |
| Evercore ISI | Outperform | $25 | Jan 6, 2026 |
| Citigroup | Buy | $21 | Dec 11, 2025 |
Questions about Robert W. Baird and FTRE
- What is Robert W. Baird's price target for FTRE?
- Robert W. Baird's latest stated price target for Fortrea Holdings Inc. (FTRE) is $9, from its action on Aug 4, 2025.
- What is Robert W. Baird's rating on FTRE?
- Robert W. Baird rates FTRE Outperform, a bullish rating, as of Aug 4, 2025.
- When did Robert W. Baird last change its view on FTRE?
- On Aug 4, 2025, Robert W. Baird upgrades to Outperform from Neutral, price target $9.
- How does Robert W. Baird's FTRE target compare with other analysts?
- Across 8 firms with a FTRE price target in the last 12 months, the median target is $22.
More FTRE rating histories
All Robert W. Baird ratingsFTRE news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.